Syngene International to Invest up to USD 56 Million in its Wholly Owned Subsidiary Syngene USA Inc

Syngene International Ltd, a leading biopharmaceutical company, has announced its intention to invest up to USD 56 Million in equity share capital of its wholly owned subsidiary, Syngene USA Inc (SUSA). The investment will be utilized to finance the cost of acquiring a biologics facility from Emergent Manufacturing Operations Baltimore, LLC, and for general corporate and day-to-day operating requirements. SUSA, incorporated in Delaware, USA in August 2017, serves as a strategic arm to expand Syngene's presence in the US market. The investment is expected to be completed by March 31, 2026.